echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Nafuraphine Hydrochloride Orally Disintegrating Tablet, a joint product of 3SBio and Toray of Japan, submitted a marketing application

    Nafuraphine Hydrochloride Orally Disintegrating Tablet, a joint product of 3SBio and Toray of Japan, submitted a marketing application

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    Hemodialysis patients are often accompanied by anemia, high blood pressure, abnormal calcium and phosphorus metabolism, hyperparathyroidism, pruritus and other complications.


    Nafuraphine hydrochloride is a selective opioid κ receptor agonist independently developed by Toray Co.


    The new drug listing application in China is based on the results of a randomized, double-blind, placebo-controlled multi-center bridging clinical study completed in China.


    Dr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.